Novo Nordisk A/S (NONOF)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Novo Nordisk A/S (NONOF) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Die Aktie erzielt 52/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 17. März 2026Novo Nordisk A/S (NONOF) Gesundheitswesen & Pipeline-Uebersicht
Novo Nordisk A/S, a leading healthcare company specializing in diabetes and obesity care, leverages its established global presence and innovative pharmaceutical products to maintain a strong market position within the biotechnology sector, underscored by a robust profit margin and significant dividend yield.
Investmentthese
Novo Nordisk A/S presents a notable research candidate within the healthcare sector, driven by its strong market position in diabetes and obesity care. With a market capitalization of $170.17 billion and a profit margin of 33.1%, the company demonstrates financial stability and profitability. The dividend yield of 4.68% offers an attractive return for investors. Growth catalysts include the increasing global prevalence of diabetes and obesity, driving demand for Novo Nordisk's innovative treatments. Potential risks include regulatory challenges and competition from other pharmaceutical companies. The company's beta of 0.27 suggests relatively low volatility compared to the overall market.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $170.17 billion, reflecting Novo Nordisk's significant presence in the healthcare sector.
- Profit margin of 33.1%, indicating strong profitability and efficient operations.
- Gross margin of 81.0%, showcasing the company's ability to maintain high pricing power and manage production costs effectively.
- Dividend yield of 4.68%, providing an attractive income stream for investors.
- Beta of 0.27, suggesting lower volatility compared to the overall market, making it a relatively stable investment.
Wettbewerber & Vergleichsunternehmen
Staerken
- Strong market position in diabetes and obesity care.
- Extensive portfolio of patented pharmaceutical products.
- Global distribution network.
- High profit margin.
Schwaechen
- Dependence on a limited number of key products.
- Exposure to patent expiration risks.
- Vulnerability to generic competition.
- Operational risks associated with manufacturing and supply chain.
Katalysatoren
- Upcoming: Potential regulatory approvals for new diabetes and obesity treatments.
- Ongoing: Increasing global prevalence of diabetes and obesity driving demand for Novo Nordisk's products.
- Ongoing: Expansion into emerging markets with large patient populations.
- Ongoing: Strategic collaborations and acquisitions to expand product portfolio.
- Ongoing: Continued investment in research and development of innovative therapies.
Risiken
- Potential: Regulatory challenges and pricing pressures in key markets.
- Potential: Competition from other pharmaceutical companies developing similar treatments.
- Potential: Patent expiration risks and generic competition.
- Ongoing: Economic downturns and healthcare spending cuts impacting demand for products.
- Ongoing: Product liability claims and litigation.
Wachstumschancen
- Expansion in Emerging Markets: Novo Nordisk has a significant opportunity to expand its presence in emerging markets, where the prevalence of diabetes and obesity is rapidly increasing. These markets offer substantial growth potential due to their large populations and increasing healthcare spending. By tailoring its product offerings and distribution strategies to meet the specific needs of these markets, Novo Nordisk can capture a larger share of the global diabetes and obesity care market. Timeline: Ongoing.
- Development of Novel Therapies: Investing in the research and development of novel therapies for diabetes, obesity, and related chronic diseases represents a significant growth opportunity for Novo Nordisk. By developing innovative treatments with improved efficacy and safety profiles, the company can differentiate itself from competitors and capture a larger share of the market. This includes exploring new drug delivery systems and personalized medicine approaches. Market size: Multi-billion dollar potential. Timeline: Ongoing.
- Strategic Collaborations and Acquisitions: Novo Nordisk can pursue strategic collaborations and acquisitions to expand its product portfolio and geographic reach. Partnering with or acquiring companies with complementary technologies or market access can accelerate growth and enhance the company's competitive position. This includes exploring opportunities in areas such as digital health and telemedicine. Timeline: Ongoing.
- Focus on Preventative Care: Novo Nordisk can expand its focus on preventative care and early intervention strategies to address the root causes of diabetes and obesity. By developing and marketing products and services that promote healthy lifestyles and prevent the onset of these diseases, the company can tap into a growing market for preventative healthcare solutions. Timeline: Ongoing.
- Leveraging Digital Health Technologies: Integrating digital health technologies into its product offerings and services represents a significant growth opportunity for Novo Nordisk. This includes developing mobile apps, wearable devices, and telehealth platforms that enable patients to better manage their diabetes and obesity. By leveraging digital health technologies, Novo Nordisk can improve patient engagement, adherence, and outcomes. Timeline: Ongoing.
Chancen
- Expansion in emerging markets.
- Development of novel therapies.
- Strategic collaborations and acquisitions.
- Focus on preventative care.
Risiken
- Regulatory challenges and pricing pressures.
- Competition from other pharmaceutical companies.
- Economic downturns and healthcare spending cuts.
- Product liability claims and litigation.
Wettbewerbsvorteile
- Strong brand reputation and established market leadership in diabetes and obesity care.
- Extensive portfolio of patented pharmaceutical products.
- Global distribution network and established relationships with healthcare providers.
- Significant investment in research and development, leading to innovative therapies.
Ueber NONOF
Founded in 1923 and headquartered in Bagsvaerd, Denmark, Novo Nordisk A/S has evolved into a global healthcare company focused on diabetes and obesity care, as well as biopharmaceuticals. The company operates through two primary segments: Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment offers a range of products, including insulins, GLP-1 and related delivery systems, oral antidiabetic products, and treatments for obesity and other chronic diseases. The Biopharmaceuticals segment provides products in the areas of haemophilia, growth disorders, and hormone replacement therapy. Novo Nordisk's commitment to research and development is evident through its collaboration agreements with companies like Gilead Sciences, Inc. and Lumen Bioscience, Inc., aimed at exploring innovative strategies for delivering oral biologics for cardiometabolic diseases. With a workforce of over 77,000 employees, Novo Nordisk continues to expand its reach and impact in the global healthcare market, driven by its dedication to improving patient outcomes and addressing unmet medical needs.
Was das Unternehmen tut
- Researches and develops pharmaceutical products.
- Manufactures pharmaceutical products.
- Markets pharmaceutical products globally.
- Offers treatments for diabetes and obesity.
- Provides products for haemophilia, growth disorders, and hormone replacement therapy.
- Collaborates with other companies to develop new therapies.
Geschaeftsmodell
- Develops and manufactures pharmaceutical products for diabetes, obesity, and other chronic diseases.
- Markets and sells these products through a global distribution network.
- Generates revenue through product sales and licensing agreements.
- Reinvests a portion of its revenue into research and development to innovate new therapies.
Branchenkontext
Novo Nordisk operates in the biotechnology industry, a segment of the healthcare sector characterized by rapid innovation and high growth potential. The increasing global prevalence of diabetes and obesity is driving demand for innovative treatments, benefiting companies like Novo Nordisk. The competitive landscape includes major pharmaceutical companies such as AZNCF (AstraZeneca), CMXHF (ChemoMetec A/S), and CSLLY (Sanofi), each vying for market share in the diabetes and obesity care market. The industry is subject to stringent regulatory requirements and faces ongoing pricing pressures.
Wichtige Kunden
- Patients with diabetes, obesity, haemophilia, growth disorders, and hormone deficiencies.
- Healthcare providers, including physicians, nurses, and hospitals.
- Pharmacies and distributors.
- Government healthcare systems and insurance companies.
Finanzdaten
Chart & Info
Novo Nordisk A/S (NONOF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus
Zacks · 20. Feb. 2026
-
Hims & Hers to Buy Australian Telehealth Provider Eucalyptus in $1.15 Billion Deal
Barrons.com · 19. Feb. 2026
-
Novo Nordisk Faces Dual FDA Scrutiny And Legal Fights Over Obesity Drugs
Simply Wall St. · 14. Feb. 2026
-
Novo Nordisk’s Legal Offensive On Compounded Obesity Drugs And Investor Implications
Simply Wall St. · 13. Feb. 2026
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer NONOF.
Kursziele
Wall-Street-Kurszielanalyse fuer NONOF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von NONOF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Aktuelle Nachrichten
Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus
Hims & Hers to Buy Australian Telehealth Provider Eucalyptus in $1.15 Billion Deal
Novo Nordisk Faces Dual FDA Scrutiny And Legal Fights Over Obesity Drugs
Novo Nordisk’s Legal Offensive On Compounded Obesity Drugs And Investor Implications
Fuehrung: Maziar Mike Doustdar
Unknown
Information on Maziar Mike Doustdar's background is not available in the provided context. Without specific details, it is impossible to provide a comprehensive bio, including career history, education, previous roles, or credentials. His professional experience and qualifications remain unknown.
Erfolgsbilanz: Information on Maziar Mike Doustdar's track record is not available in the provided context. Without specific details, it is impossible to assess key achievements, strategic decisions, or company milestones under their leadership. His previous performance and contributions remain unknown.
NONOF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Novo Nordisk A/S (NONOF) may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other stocks often have less stringent listing standards and regulatory oversight, resulting in higher risks for investors.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited information availability due to lower disclosure requirements.
- Potential for price manipulation and fraud.
- Higher bid-ask spreads and lower trading volumes.
- Increased volatility and price swings.
- Lack of regulatory oversight compared to major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Check for any legal or regulatory issues.
- Evaluate the company's stock price history and trading volume.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investments.
- Established history as Novo Nordisk A/S, founded in 1923.
- Global presence and operations in multiple countries.
- Significant market capitalization, despite being traded OTC.
- Presence in the healthcare sector with a focus on diabetes and obesity care.
- Collaboration agreements with reputable companies like Gilead Sciences, Inc.
Haeufige Fragen zu NONOF
What are the key factors to evaluate for NONOF?
Novo Nordisk A/S (NONOF) currently holds an AI score of 52/100, indicating moderate score. Key strength: Strong market position in diabetes and obesity care.. Primary risk to monitor: Potential: Regulatory challenges and pricing pressures in key markets.. This is not financial advice.
How frequently does NONOF data refresh on this page?
NONOF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NONOF's recent stock price performance?
Recent price movement in Novo Nordisk A/S (NONOF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong market position in diabetes and obesity care.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider NONOF overvalued or undervalued right now?
Determining whether Novo Nordisk A/S (NONOF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying NONOF?
Before investing in Novo Nordisk A/S (NONOF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding NONOF to a portfolio?
Potential reasons to consider Novo Nordisk A/S (NONOF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Strong market position in diabetes and obesity care.. Additionally: Extensive portfolio of patented pharmaceutical products.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of NONOF?
Yes, most major brokerages offer fractional shares of Novo Nordisk A/S (NONOF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track NONOF's earnings and financial reports?
Novo Nordisk A/S (NONOF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for NONOF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may not be exhaustive.
- OTC market data may be limited and less reliable than exchange-listed data.
- AI analysis is pending and may provide further insights.